Infigratinib - Novartis Oncology

Drug Profile

Infigratinib - Novartis Oncology

Alternative Names: BGJ-398; NVP-BGJ398

Latest Information Update: 05 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; Novartis; Novartis Oncology
  • Class Aniline compounds; Antineoplastics; Methylurea compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Haematological malignancies
  • Discontinued Bladder cancer; Glioblastoma; Malignant melanoma; Solid tumours

Most Recent Events

  • 30 Jan 2018 Infigratinib licensed to BridgeBio Pharma
  • 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 01 Apr 2017 Pharmacodynamics and efficacy data from a phase II trial in Cholangiocarcinoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top